Advertisement
UK markets open in 1 hour 11 minutes
  • NIKKEI 225

    38,011.76
    +383.28 (+1.02%)
     
  • HANG SENG

    17,698.32
    +413.78 (+2.39%)
     
  • CRUDE OIL

    83.97
    +0.40 (+0.48%)
     
  • GOLD FUTURES

    2,347.60
    +5.10 (+0.22%)
     
  • DOW

    38,085.80
    -375.12 (-0.98%)
     
  • Bitcoin GBP

    51,454.08
    +26.12 (+0.05%)
     
  • CMC Crypto 200

    1,388.81
    +6.24 (+0.45%)
     
  • NASDAQ Composite

    15,611.76
    -100.99 (-0.64%)
     
  • UK FTSE All Share

    4,387.94
    +13.88 (+0.32%)
     

How AstraZeneca Performed in the First Quarter

How AstraZeneca Performed in the First Quarter

In the first quarter, AstraZeneca’s (AZN) sales were boosted by strong product launches and newer medicines and partially offset by a decrease in Crestor sales. AstraZeneca’s total revenue fell 4% YoY (year-over-year) to $5.2 billion in Q1 2018. AstraZeneca expects to return to growth in fiscal 2018.